Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma

[This corrects the article DOI: 10.3389/fonc.2022.1021632.].

Saved in:

Bibliographic Details
Published in:	Frontiers in oncology Vol. 12; p. 1124912
Main Authors:	Prasopporn, Sunisa, Suppramote, Orawan, Ponvilawan, Ben, Jamyuang, Chanette, Chanthercrob, Jantappapa, Chaiboonchoe, Amphun, More-Krong, Pimkanya, Kongsri, Kamonchanok, Suntiparpluacha, Monthira, Chanwat, Rawisak, Korphaisarn, Krittiya, Okada, Seiji, Sampattavanich, Somponnat, Jirawatnotai, Siwanon
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 06-01-2023
Subjects:	acquired vulnerability cholangiocarcinoma Gemcitabine plus Cisplatin therapy LCL161 multidrug resistance Oncology SMAC mimetics SMAC mimetics multidrug resistance Gemcitabine plus Cisplatin therapy LCL161 cholangiocarcinoma acquired vulnerability
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	[This corrects the article DOI: 10.3389/fonc.2022.1021632.].
Bibliography:	corrigendum SourceType-Other Sources-1 content type line 63 ObjectType-Correction/Retraction-1 Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
ISSN:	2234-943X 2234-943X
DOI:	10.3389/fonc.2022.1124912